Piedmont Animal Health
Pharmaceutical development for companion animal therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $210m Valuation: $210m | Acquisition | |
| Total Funding | 000k | ||
Related Content
Piedmont Animal Health is a specialty pharmaceutical company focused on developing and commercializing therapeutics for companion animals. Founded in 2001 by Roland Johnson in Greensboro, North Carolina, the company established itself by creating new formulations and drug delivery systems for known pharmaceutical compounds. Johnson, who previously co-founded Blue Ridge Pharmaceuticals, has a background with Ciba-Geigy, a predecessor to Novartis, and brought extensive industry experience to the venture.
The company's business model centers on the research and development of novel animal health products which are then out-licensed to major pharmaceutical corporations for commercialization. A key innovation was the development of a soft, palatable chewable platform for drug delivery, which offers a more convenient method for administering medication to pets. This technology was sold to Bayer HealthCare Animal Health in 2010 and is used in products like Advantus, a flea medicine, and Quellin, a pain reliever. Piedmont has also developed products such as a single-dose treatment for canine ear infections and a tick spray, both of which were also sold to Bayer. The firm actively collaborates with large animal health companies like Bayer and Zoetis.
Over the years, Piedmont Animal Health secured strategic investments from firms including Sumitomo Corporation of Americas, AustralianSuper, and Talu Ventures. In July 2022, the company was acquired by Dechra Pharmaceuticals for approximately $210 million. This acquisition was intended to accelerate Dechra's product pipeline, adding a portfolio of eight novel products in development for cats and dogs within therapeutic areas such as dermatology, pain management, and anti-infectives. At the time of the acquisition, Piedmont had a development team of 19 people.
Keywords: animal health, veterinary pharmaceuticals, drug delivery systems, companion animals, parasitology, pharmaceutical development, pet therapeutics, product licensing, chewable medication, animal drug formulation, Dechra Pharmaceuticals, Roland Johnson, canine health, feline health, drug development, veterinary medicine, pet care, anti-infectives, dermatology, pain management